PL441319A1 - Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro - Google Patents

Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro

Info

Publication number
PL441319A1
PL441319A1 PL441319A PL44131922A PL441319A1 PL 441319 A1 PL441319 A1 PL 441319A1 PL 441319 A PL441319 A PL 441319A PL 44131922 A PL44131922 A PL 44131922A PL 441319 A1 PL441319 A1 PL 441319A1
Authority
PL
Poland
Prior art keywords
colorectal cancer
timp
protein biomarkers
vitro method
diagnosing colorectal
Prior art date
Application number
PL441319A
Other languages
English (en)
Inventor
Piotr DZIĘGIEL
Łukasz Zadka
Agnieszka Rusak
Original Assignee
Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu filed Critical Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu
Priority to PL441319A priority Critical patent/PL441319A1/pl
Priority to EP23461600.1A priority patent/EP4286854A3/en
Publication of PL441319A1 publication Critical patent/PL441319A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest zestaw biomarkerów białkowych do diagnozowania in vitro wczesnego stadium raka jelita grubego albo raka jelita grubego zawierający TIMP-1, TIMP-2, IL8, GRO-a, HGF i Ang-1. Kolejnym przedmiotem zgłoszenia jest sposób diagnozowania in vitro wczesnego stadium raka jelita grubego albo raka jelita grubego obejmujący ocenę poziomu ekspresji w pęcherzykach pozakomórkowych co najmniej dwóch biomarkerów z grupy obejmującej TIMP-1, TIMP-2, IL8, GRO-a, HGF i Ang-1.
PL441319A 2022-05-31 2022-05-31 Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro PL441319A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL441319A PL441319A1 (pl) 2022-05-31 2022-05-31 Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro
EP23461600.1A EP4286854A3 (en) 2022-05-31 2023-05-31 Set of protein biomarkers and method for diagnosing colorectal cancer in vitro

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441319A PL441319A1 (pl) 2022-05-31 2022-05-31 Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro

Publications (1)

Publication Number Publication Date
PL441319A1 true PL441319A1 (pl) 2023-12-04

Family

ID=87514370

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441319A PL441319A1 (pl) 2022-05-31 2022-05-31 Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro

Country Status (2)

Country Link
EP (1) EP4286854A3 (pl)
PL (1) PL441319A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2012006681A1 (en) * 2010-07-14 2012-01-19 Commonwealth Scientific And Industrial Research Organisation Diagnostic for colorectal cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
CA2838728A1 (en) * 2011-06-07 2012-12-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for cancer
ES2942585T3 (es) 2012-04-26 2023-06-02 Stichting Vumc Biomarcadores
WO2019004430A1 (ja) 2017-06-30 2019-01-03 国立研究開発法人医薬基盤・健康・栄養研究所 大腸がんを検出するためのバイオマーカー
CN113767289A (zh) 2019-05-08 2021-12-07 德国癌症研究公共权益基金会 结直肠癌筛选检查及早期检测方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2012006681A1 (en) * 2010-07-14 2012-01-19 Commonwealth Scientific And Industrial Research Organisation Diagnostic for colorectal cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUANG, CH. IIN.: "Oncotarget, 2017, vol. 8 (No. 14), 23459-23469", "HEPATOCYTE GROWTH FACTOR IS A PROGNOSTIC MARKER IN PATIENTS WITH COLORECTAL CANCER: A META-ANALYSIS" *

Also Published As

Publication number Publication date
EP4286854A3 (en) 2024-02-14
EP4286854A2 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
Yang et al. TIMP1 mRNA in tumor-educated platelets is diagnostic biomarker for colorectal cancer
Liot et al. Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker
Cvetkovic et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer
Barber et al. Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer
Kobayashi et al. Distribution of lymph node metastasis is a prognostic index in patients with stage III colon cancer
Nagai et al. Metachronous intraductal papillary mucinous neoplasms disseminate via the pancreatic duct following resection
Mertz et al. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer
Davila et al. Postoperative 30-day mortality following surgical resection for colorectal cancer in veterans: changes in the right direction
Sangoi et al. Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact
Makboul et al. A simple immunohistochemical panel could predict and correlate to clinicopathologic and molecular subgroups of urinary bladder urothelial carcinoma
Stallone et al. Semaphorin 3F expression is reduced in pregnancy complicated by preeclampsia. An observational clinical study
Rompen et al. Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer
PL441319A1 (pl) Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro
Mathey-Andrews et al. Segmentectomy vs lobectomy for patients with 2-to 3-cm non-small cell lung cancer
González et al. Adenoma-like adenocarcinoma: clinicopathologic characterization of a newly recognized subtype of colorectal carcinoma
Sapci et al. Factors associated with noncomplete mesorectal excision following surgery for rectal adenocarcinoma
Kuratomi et al. Diffuse expression of laminin γ2 chain in disseminating and infiltrating cancer cells indicates a highly malignant state in advanced tongue cancer
Apolo et al. Summary of the 8th Annual Bladder Cancer Think Tank: collaborating to move research forward
Cienfuegos et al. Screening-detected colorectal cancers show better long-term survival compared with stage-matched symptomatic cancers
He et al. Use of mesothelin as a tumor-associated antigen in cervical squamous cell carcinoma
Vanoli et al. Mismatch repair deficiency as prognostic factor for stage III small bowel adenocarcinoma: A multicentric international study
Yin et al. Clinical significance of neuropilin-2 expression in laryngeal squamous cell carcinoma
Šundov et al. Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke’s B colon cancer
Hofmann et al. Prognostic relevance of disseminated tumour cells in bone marrow of patients with transitional cell carcinoma
Janeva Clinical significance of immunohistochemistry in breast cancer diagnostics